Marinus Pharmaceuticals
MRNS
#9684
Rank
โ‚น1.50 B
Marketcap
โ‚น27.23
Share price
4.30%
Change (1 day)
-94.50%
Change (1 year)

P/E ratio for Marinus Pharmaceuticals (MRNS)

P/E ratio as of November 2024 (TTM): -2.93

According to Marinus Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.93. At the end of 2022 the company had a P/E ratio of -9.71.

P/E ratio history for Marinus Pharmaceuticals from 2014 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-9.71119.8%
2021-4.427.15%
2020-4.1290.34%
2019-2.17-32.1%
2018-3.19-67.95%
2017-9.951348.35%
2016-0.6871-84.89%
2015-4.55-46.25%
2014-8.46

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.2783-90.50%๐Ÿ‡บ๐Ÿ‡ธ USA
0.9783-133.39%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0001-99.99%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
45.3-1,647.50%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.